PRAX Praxis Precision Medicines (PRAX) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001689548
Congress · 1
Insider buyers, 180 days
0
Funds added, last quarter
182
13F, latest reported quarter
Conversions, 180 days
2
Codes C/M, not in net · $826.0K priced
What the filings say about PRAX
Insiders, 180 days
-$3.6M net sold
1 seller · 0% of sales under a 10b5-1 plan
Congress, 1 year
1 bought · 0 sold
Latest: purchase, 2026-09-29
Praxis Precision Medicines insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Praxis Precision Medicines, Inc. insiders sold a net $3.6M of stock across 54 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Oct 5, 2023.
- The trade is 0.1% of the 13,927 shares held after it.
- No other insider sold within 30 days.
- 182 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director DeSimone Jill sold about $3.0K of PRAX on Jun 24, 2026; 182 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Oct 5, 2023.
- The trade is 40.3% of the 3,174 shares held after it.
- No other insider sold within 30 days.
- 182 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director DeSimone Jill sold about $402.8K of PRAX on Jun 24, 2026; 182 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Oct 5, 2023.
- The trade is 35.8% of the 2,337 shares held after it.
- No other insider sold within 30 days.
- 182 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director DeSimone Jill sold about $264.2K of PRAX on Jun 24, 2026; 182 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Oct 5, 2023.
- The trade is 11.3% of the 4,453 shares held after it.
- No other insider sold within 30 days.
- 182 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director DeSimone Jill sold about $158.1K of PRAX on Jun 24, 2026; 182 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Oct 5, 2023.
- The trade is 20.3% of the 4,957 shares held after it.
- No other insider sold within 30 days.
- 182 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director DeSimone Jill sold about $314.1K of PRAX on Jun 24, 2026; 182 funds added in the latest 13F quarter.54 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$3.6M over 180 days
below 76% of Pharma & Biotech
Congress
1 member bought in the last year
the lowest in Pharma & Biotech
Funds
182 funds bought in last quarter
more than 87% of Pharma & Biotech
Revenue
-100.0% year over year
the lowest in Pharma & Biotech
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
16.3% of the float short (float per yahoo 2026-10-27) · 7.4 days to cover · settled 2026-10-15
more than 84% of Pharma & Biotech
What changed in the last 30 days
Oct 28Insider selling stopped: no sales in 90 days after 12 in the prior 90
Why it matters
The absence is the signal: 12 sales in one 90-day window and none in the next is a change of behaviour, not a filing.
Oct 12Rep. Gilbert Cisneros sold $1.0K to $15K, disclosed 13 days after the trade
Why it matters
House members report a bracket, not an exact amount, and have 45 days to do it; the trade is weeks old when it becomes public.
Watch PRAX
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+50.2%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns PRAX: institutional holders (13F)
13F holdings, latest reported quarter
3,421,374 sh
$1.1B
2,316,907 sh
$775.7M
2,292,585 sh
$767.5M
2,035,986 sh
$681.6M
1,753,198 sh
$587.0M
Congress trades in PRAX
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Bought 2026-09-29 · disclosed 13 days later
$1,001 - $15,000
Bought 2026-07-30 · disclosed 36 days later
$1,001 - $15,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
PRAX planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
DeSimone Jill
Filed 2026-06-24
$3.6M
PRAX mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Global X Genomics & Biotechnology ETF
$2.2M position · as of 2026-05-31
4.0%
Select Biotechnology Portfolio
$130.0M position · as of 2026-05-31
2.5%
Janus Henderson Global Life Sciences Fund
$127.0M position · as of 2026-06-30
2.2%
Driehaus Micro Cap Growth Fund
$12.3M position · as of 2026-06-30
2.1%
Franklin Biotechnology Discovery Fund
$22.1M position · as of 2026-07-31
1.9%
Driehaus Small/Mid Cap Growth Fund
$2.1M position · as of 2026-06-30
1.8%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
13 registered trials, 8 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
1
Phase 1
0 active
3
Phase 2
1 active
5
Phase 3
5 active
1
Not applicable
0 active
3
Multi-phase
2 active
What changed recently
Essential 3 - Decentralized, Phase 3 Study Evaluating the Safety and Efficacy of Ulixaca
2026-10-07 · Active Not Recruiting → Recruiting
Phase 3
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return · Marcio Souza
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$8.7M
$55.5M
$3.0M
-64%
+25%
2024
$13.4M
$20.6M
$4.0M
-91%
-7%
2023
$2.1M
$1.4M
$933.5K
-97%
-6%
2022
$6.0M
-$17.6M
$2.5M
-96%
-10%
2021
$10.9M
-$62.2M
$4.1M
-64%
+0%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $3.6M sold by insiders over 180 days, 182 funds added last quarter, 1 House member(s) bought in 12 months, disclosed weeks after the trade. Each figure is a federal filing, dated the day it went public.
PRAX financials
Revenue growth
-100.0%
XBRL, annual
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$0
four quarters, 2025-01-01 to 2025-12-31
Revenue, TTM PRAX
| FY Dec 2025 | $0 |
| FY Dec 2024 | $8.6M |
| FY Dec 2023 | $2.4M |
| FY Dec 2022 | $0 |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | $0 |
| Sep 2025 | $0 |
| Jun 2025 | $0 |
| Mar 2025 | $0 |
| Dec 2024 | $7.5M |
| Sep 2024 | $302.0K |
At each fiscal year end
Single quarter
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Net margin, TTM PRAX
| FY Dec 2025 | n/a |
| FY Dec 2024 | -2,137% |
| FY Dec 2023 | -5,038% |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | -786.3% |
| Sep 2024 | -17,189% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$305.4M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM PRAX
| FY Dec 2025 | -$249.1M |
| FY Dec 2024 | n/a |
| FY Dec 2023 | -$111.2M |
| FY Dec 2022 | -$185.5M |
| FY Dec 2021 | -$125.6M |
| Jun 2026 | -$77.8M |
| Mar 2026 | -$86.2M |
| Dec 2025 | -$76.3M |
| Sep 2025 | -$65.1M |
| Jun 2025 | -$54.7M |
| Mar 2025 | -$53.0M |
| Dec 2024 | -$56.1M |
| Sep 2024 | -$27.5M |
At each fiscal year end
Single quarter
Debt to equity
n/a
no debt line filed
Debt to equity PRAX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt line filed
Cash flow to debt PRAX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-38.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity PRAX
| FY Dec 2025 | -45.8% |
| FY Dec 2024 | -71.0% |
| FY Dec 2023 | -169.1% |
| FY Dec 2022 | -130.9% |
| FY Dec 2021 | -62.1% |
| Jun 2026 | -38.8% |
| Mar 2026 | -35.3% |
| Dec 2025 | -45.8% |
| Sep 2025 | -75.2% |
| Jun 2025 | -61.0% |
| Mar 2025 | -63.6% |
| Dec 2024 | -71.0% |
| Sep 2024 | -64.3% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-36.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets PRAX
| FY Dec 2025 | -42.6% |
| FY Dec 2024 | -64.0% |
| FY Dec 2023 | -121.4% |
| FY Dec 2022 | -104.9% |
| FY Dec 2021 | -56.1% |
| Jun 2026 | -36.8% |
| Mar 2026 | -33.7% |
| Dec 2025 | -42.6% |
| Sep 2025 | -67.2% |
| Jun 2025 | -56.2% |
| Mar 2025 | -58.3% |
| Dec 2024 | -64.0% |
| Sep 2024 | -57.8% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital PRAX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-43.3%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed PRAX
| FY Dec 2025 | -49.3% |
| FY Dec 2024 | -77.3% |
| FY Dec 2023 | -165.2% |
| FY Dec 2022 | -128.3% |
| FY Dec 2021 | -61.8% |
| Jun 2026 | -43.3% |
| Mar 2026 | -38.6% |
| Dec 2025 | -49.3% |
| Sep 2025 | -80.6% |
| Jun 2025 | -65.9% |
| Mar 2025 | -69.5% |
| Dec 2024 | -77.3% |
| Sep 2024 | -69.3% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing PRAX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no debt line filed
Enterprise value PRAX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-4.1%
TTM free cash flow over market value at close 2026-10-26
FCF yield PRAX
| FY Dec 2025 | -3.4% |
| FY Dec 2024 | n/a |
| FY Dec 2023 | -3.9% |
| FY Dec 2022 | -11.0% |
| FY Dec 2021 | -0.9% |
| Jun 2026 | -3.3% |
| Mar 2026 | -3.1% |
| Dec 2025 | -3.4% |
| Sep 2025 | -20.5% |
| Jun 2025 | -22.3% |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing PRAX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $0 | $8.6M | $2.4M | $0 |
| Operating income | -$326.2M | -$200.2M | -$126.4M | -$215.0M |
| Net income | -$303.0M | -$183.0M | -$123.0M | -$214.0M |
| EPS (diluted) | -13.48 | -10.21 | -18.69 | -69.65 |
| Operating cash flow | -$249.1M | -$131.8M | -$111.1M | -$185.0M |
| Cash | $357.3M | $215.4M | $81.3M | $61.6M |
SEC XBRL, fiscal years, as known on 2026-10-28
PRAX Stock Sonar score 5/7 axes
Find similar shapesComparePRAX ranks highest on institutional and government (63rd percentile) and profitability (58th), and lowest on growth (1st), among Pharma & Biotech peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
PRAX filings, in plain words
Are Praxis Precision Medicines insiders buying or selling PRAX?
In the 180 days to 2026-10-28, Praxis Precision Medicines insiders were net sellers, a net $3.6M across purchases and sales reported on Form 4, by 1 seller.
Have members of Congress traded PRAX?
Yes. In the year to 2026-10-28, 1 House member disclosed buying PRAX and 0 House members disclosed selling it; the latest on record is a purchase by Gilbert Cisneros dated 2026-09-29.
Read the full summary
In the 180 days to 2026-10-28, Praxis Precision Medicines insiders were net sellers of PRAX, a net $3.6M across purchases and sales reported on Form 4 by 1 seller. None of the 12 insider sales was flagged as made under a Rule 10b5-1 plan. In the year to 2026-10-28, 1 member of Congress disclosed buying PRAX and 0 members disclosed selling it; the latest on record is a purchase by Gilbert Cisneros dated 2026-09-29. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
